These biomechanical gait results provide strong independent, objective evidence of genuine neural recovery, significantly de-risking the upcoming Phase 3 RESTORE study. With the stock at ~$171M market cap and positive Phase 1b/2a data across multiple domains (electrophysiology, functional hand use, QoL, and now gait), NVG-291 has potential as a first-in-class therapy for chronic tetraplegia. Monitor for site activation and patient enrollment milestones for RESTORE in mid-2026.
Price Chart
Executive Summary
NervGen announced positive independent, blinded biomechanical gait analyses from the Phase 1b/2a CONNECT SCI study, demonstrating statistically significant improvement in gait quality (p=0.0197) with NVG-291 versus placebo. 100% of NVG-291 subjects were classified as responders versus 10% for placebo (p=0.0001). The company is on track to initiate the Phase 3 RESTORE registrational study in mid-2026.
Key Facts
- NVG-291 demonstrated statistically significant improvement in gait quality (GTE=+0.45; 95% CI: +0.15 to +0.72; p=0.0197)
- 100% (10/10) of NVG-291 subjects classified as responders vs 10% (1/10) for placebo (p=0.0001)
- Speed-effort dissociation shows speed gains driven by restored neural control, not compensation
- Consistent statistically significant benefit across all three recovery measures: coordination (p=0.007), mechanical effort (p=0.038), postural stability (p=0.044)
- Company on track to initiate Phase 3 RESTORE registrational study in mid-2026 with site activation underway
- FDA Fast Track and EMA Orphan Drug designations for NVG-291 for SCI treatment
Financial Impact
No financial figures provided in filing; pre-revenue clinical-stage biopharma. Positive Phase 1b/2a results de-risk Phase 3 and increase probability of regulatory approval and commercial value.
Risk Factors
- Phase 3 clinical trials may fail to replicate Phase 1b/2a results
- Pre-revenue company needs additional financing to complete Phase 3
- Regulatory approval not guaranteed even with positive data
- Competition from other SCI therapies in development
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001104659-26-066307 |
| Document: tm2615621d1_6k.htm | 0001104659-26-066307 |
| Document: 0001104659-26-066307-index-headers.html | 0001104659-26-066307 |
| Document: 0001104659-26-066307-index.html | 0001104659-26-066307 |
| Document: 0001104659-26-066307.txt | 0001104659-26-066307 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 25, 2026 4w ago | 6-K | $1.88 $1.81 | ▲ +3.72% | ▲ +4.93% | $1.42 (+24.62%) |
Sep 25, 2026 4w ago | Press Release | $1.88 $1.81 | ▼ −3.72% | ▼ −4.93% | $1.42 (−24.62%) |
Sep 24, 2026 4w ago | 6-K | $2.02 $1.76 | ▼ −12.87% | ▼ −12.46% | $1.42 (−29.85%) |
Aug 13, 2026 10w ago | 6-K | $1.76 $1.76 | · 0.00% | ▲ +1.96% | $1.42 (−19.48%) |
Aug 13, 2026 10w ago | Press Release | $1.76 $1.76 | · 0.00% | ▲ +1.96% | $1.42 (−19.48%) |
Jul 2, 2026 16w ago | 6-K | $2.12 $1.86 | ▲ +12.26% | ▲ +13.19% | $1.42 (+33.16%) |
Jun 1, 2026 20w ago | 6-K | $2.00 $1.81 | ▲ +9.50% | ▲ +6.54% | $1.42 (+29.15%) |
May 27, 2026 21w ago | EFFECT | $2.07 $1.91 | ▼ −7.73% | ▼ −8.20% | $1.42 (−31.54%) |
May 26, 2026 21w ago | 6-K | $2.07 $2.00 | ▼ −3.38% | ▼ −4.59% | $1.42 (−31.54%) |
May 22, 2026 22w ago | 6-K | $2.13 $2.00 | ▲ +6.10% | ▲ +7.32% | $1.42 (+33.47%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers